141307-10-0Relevant academic research and scientific papers
Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs
Fujita, Masakazu,Seki, Taketsugu,Inada, Haruaki,Shimizu, Kazuhiro,Takahama, Akane,Sano, Tetsuro
, p. 341 - 344 (2002)
A series of compounds (22-36) which possess dual-acting PAF antagonist/TxSI have been generated by the approach of linking the known PAF antagonists and TxIs, such as Ridogrel (1).
HUMAN PLASMA KALLIKREIN INHIBITORS
-
Page/Page column 188; 189, (2015/11/02)
Disclosed are compounds of formula (I), as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
